parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in hofbauer cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 19	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12879

MILR1 in microglia, braak+0.12 (p 0.760) → -0.08 (p 0.838)receipt 12887
MILR1 in dopamine neurons, braak-0.11 (p 0.784) → +0.47 (p 0.202)receipt 12888

receipt 12888: MILR1 in dopamine neurons, braak

power: full sample +0.21 (p 0.408, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.28 (p 0.261, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.310, n 18). could be the mix.
skeptic: leave-one-out range +0.11 to +0.32, sign flips 0; without severely affected donors +0.21 (p 0.408, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MILR1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12887: MILR1 in microglia, braak

power: full sample +0.06 (p 0.820, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.847, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.03 (p 0.908, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.19, sign flips 3; without severely affected donors +0.06 (p 0.820, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MILR1 in microglia.

case closed: nothing better to follow up.

loading the receipts